Nevertheless, positive [18F]FDG results still require histological confirmation and assessment of ER status, and even negative [18F]FDG cannot completely exclude the possibility of recurrent breast cancer; therefore, biopsies of possible breast cancer recurrence may still be performed. This evidence concerns the gene ESR1 and breast cancer.